Attaining asthma control

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 2, 2006, Pages 119-123

  Oppenheimer, John J ^a   Li, James ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Asthma control; Asthma severity; Lung function

Indexed keywords

ASTHMA; CLINICAL PROTOCOL; DISEASE CONTROL; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; GOAL ATTAINMENT; HUMAN; INTERVENTION STUDY; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LUNG FUNCTION; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATION CONTROL; RESPONSE VARIABLE; REVIEW;

ASTHMA; HUMANS;

EID: 33746793311     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000216855.02947.33     Document Type: Review

References (43)

1. National Asthma Education and Prevention Program Expert Panel. Report. Guidelines for the Diagnosis and Management of Asthma 1991. Bethesda, MD: National Institutes of Health; 1991.
2. Sheffer AL; for the International Asthma Management Project. International consensus report on diagnosis and treatment of asthma. DJJS NIH publication 92-3091. Wur Respir J 1992; 5:601-641.
3. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002; 166:1044-1049.
4. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16:802-807.
5. Mannino DM, Homa DM, Akinbami L, et al. Surveillance for asthma - United States 1980-99. MMWR Surveil Summ 2002; 51:1-13.
6. National Asthma Education and Prevention Program Expert Panel. Report 2: Guidelines for the Diagnosis and Management of Asthma, NIH publication no. 97-4051. Bethesda, MD: National Institutes of Health; 1997.
7. Calhoun WJ, Sutton LB, Emmett A, et al. Asthma variability in patients previously treated with [beta]2-agonists alone. J Allergy Clin Immunol 2003; 112:1088-1094.
8. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Ped Pulm 1992; 13:95-100.
9. Osborne ML, Vollmer WM, Pedula KL, et al. Lack of correlation of symptoms with specialist-assessed long-term asthma severity. Chest 1999; 115:85-91.
10. Magadle R, Berar-Yanay N, Weiner P. The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea. Chest 2002; 121:329-333.
11. Bateman ED, Boushey HA, Bousquet J, et al. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004; 170:836-844. In this 1-year study, of 3421 patients with uncontrolled asthma the authors compared fluticasone with combination salmeterol and fluticasone's ability to achieve one of two rigorous, composite, guideline-based measures of asthma control. In the group who were in poor control at randomization (baseline) despite high-dose inhaled corticosteroid therapy, even with aggressive intervention (using high-dose salmeterol/fluticasone therapy), the majority were not able to achieve total asthma control. This highlights the fact that some asthmatic patients may never achieve total symptom control.
12. Li J, Oppenheimer J, Bernstein L, et al. Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005; 115 (in press).
13. Fuhlbrigge AL. Asthma severity and asthma control: symptoms, pulmonary function and inflammatory markers. Curr Opin Pulm Med 2004; 10:1-6. A wonderful review highlighting the difference between asthma control and severity.
14. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98:1016-1018.
15. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV-1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107:61-67.
16. Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV-1 is associated with risk of asthma attacks in long term follow-up. Chest 2004; 126:1875-1882.
17. Noonan M, Chervinsky P, Busse W, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152:1467-1473.
18. Okamoto LJ, Noonan M, DeBoisblanc BP, et al. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Ann Allergy Asthma Immunol 1996; 76:291-300.
19. Dryngel B, Kesten S, Champman KR. Assesment of an ambulatory care asthma program. J Asthma 1994; 31:291-300.
20. Agertoft L, Pedersen S. Effects of long term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88:373-381.
21. Otulana BA, Varma N, Bullock A, Higenbottam T. High dose nebulized steroid in the treatment of chronic steroid-dependent asthma. Repir Med 1992; 86:105-108.
22. Corren J, Hams AG, Aaronson D, et al. Efficacy and safety of loratidine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100:781-788.
23. Ogirala RG, Strum TM, Aldrick TK, et al. Single high-dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: a double-blind study. Am J Respir Crit Care Med 1995; 152:1461-1466.
24. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155:1235-1240.
25. Dryngel B, Kesten S, Champman KR. Assesment of an ambulatory care asthma program. J Asthma 1994; 31:291-300.
26. Craun-Fahrlander C, Gassner M, Grize L, et al. Comarison of responses to an asthma symptom questionnaire (ISAAC) completed by adolescents and their parents. Pediatr Pulm 1998; 25:159-166.
27. Shingo S, Zhang J, Reiss TF. Correlation of airway obstruction and patientreported endpoints in clinical studies. Eur Respir J 2001; 17:220-224.
28. Sharek PJ, Mayer MI, Loewy L, et al. Agreement among measures of asthma status; a prospective study of low-income children with moderate to severe asthma. Pediatrics 2002; 110:797-804.
29. Gendo K, Sullivan SD, Lozano P, et al. Resource costs for asthma-related care among pediatric patients in managed care. Ann Allergy Asthma Immunol 2003; 91:251-257.
30. Juniper EF, Guyatt GH, Cox FM, et al. Develpment and validation of the Mini Asthma Quality of Life Questionnaire. Eur Resp J 1999; 14:32-38.
31. Volmer WM, Markson LE, O'Connor E, et al. Association of asthma control with health care utilzation and quality of life. Am J Resp Crit Care Med 1999; 160:1647-1652.
32. Volmer WM, Markson LE, O'Connor E, et al. Association of asthma control with health care utilization: a prospective evaluation. Am J Resp Crit Care Med 2002; 165:195-199.
33. Vermeire PA, Rabe KF, Soriano JB, Maier WC. Asthma control and differences in management practices across seven European countries. Resp Med 2002; 93:142-149.
34. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875-879.
35. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Resp Crit Care Med 2000; 161:64-72.
36. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Resp Crit Care Med 1999; 159:1043-1051.
37. Perng DW, Huang HY, Lee YC, Perng RP. Leukotriene modifier vs. inhaled corticosteroid in mild-to-moderate asthma: clinical and anti-inflammatory effects. Chest 2004; 12:1693-1699.
38. Delgado-Corcoran C, Kissoon N, Murphy SP, Duckworth LJ. Exhaled nitric oxide reflects asthma severity and asthma control. Ped Crit Care Med 2004; 5:48-52.
39. Covar RA, Szefler SJ, Martin RJ, et al. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr 2003; 142:469-475.
40. Sippel JM, Holden WE, Tilles SA, et al. Exhaled nitric oxide levels correlate with measures of disease control in asthma. J Allergy Clin Immunol 2000; 106:645-650.
41. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Eng J Med 2005; 352:2163-2173.
42. Jones SL, Kittleson J, Cowan J, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164:738-743.
43. Green R, Brightling C, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet 2002; 360:1715-1721.